[go: up one dir, main page]

MX2018004021A - Formulaciones estables de fingolimod. - Google Patents

Formulaciones estables de fingolimod.

Info

Publication number
MX2018004021A
MX2018004021A MX2018004021A MX2018004021A MX2018004021A MX 2018004021 A MX2018004021 A MX 2018004021A MX 2018004021 A MX2018004021 A MX 2018004021A MX 2018004021 A MX2018004021 A MX 2018004021A MX 2018004021 A MX2018004021 A MX 2018004021A
Authority
MX
Mexico
Prior art keywords
water
fingolimod
filler
examples
insoluble
Prior art date
Application number
MX2018004021A
Other languages
English (en)
Inventor
Liu Zhi
D Kirsch John
C Chattaraj Sarat
Original Assignee
Mylan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Inc filed Critical Mylan Inc
Publication of MX2018004021A publication Critical patent/MX2018004021A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formulaciones de fingolimod libres de alcohol de azúcar. Se describen las composiciones de fingolimod, sales de este, o ésteres de este que carecen de alcoholes de azúcar. La composición puede incluir un relleno soluble en agua y un relleno insoluble en agua, además de otros excipientes comunes. En algunos ejemplos, el relleno soluble en agua es glicina y el relleno insoluble en agua es fosfato de calcio dibásico dihidratado como rellenos. En algunos ejemplos, el relleno soluble en agua y el relleno insoluble en agua se encuentran a concentraciones iguales. Las composiciones descritas pueden usarse para producir formas de dosificación de liberación inmediata que contienen hidrocloruro de fingolimod.
MX2018004021A 2015-10-02 2016-08-08 Formulaciones estables de fingolimod. MX2018004021A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562236373P 2015-10-02 2015-10-02
PCT/US2016/046002 WO2017058364A1 (en) 2015-10-02 2016-08-08 Stable formulations of fingolimod

Publications (1)

Publication Number Publication Date
MX2018004021A true MX2018004021A (es) 2018-09-11

Family

ID=58427788

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004021A MX2018004021A (es) 2015-10-02 2016-08-08 Formulaciones estables de fingolimod.

Country Status (8)

Country Link
US (1) US20180280322A1 (es)
EP (1) EP3355863A4 (es)
AU (1) AU2016331648A1 (es)
BR (1) BR112018006648A2 (es)
CA (1) CA3000186A1 (es)
IL (1) IL258420A (es)
MX (1) MX2018004021A (es)
WO (1) WO2017058364A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1009654B (el) * 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2465492T3 (pl) * 2007-10-12 2015-11-30 Novartis Ag Mieszaniny zawierające modulatory receptora 1-fosforanu sfingozyny (S1P)
US20130095177A1 (en) * 2010-04-22 2013-04-18 Ratiopharm Gmbh Method of preparing an oral dosage form comprising fingolimod
US20140199382A1 (en) * 2013-01-11 2014-07-17 Cadila Healthcare Limited Stable pharmaceutical compositions of an s1p receptor agonist
US20160128951A1 (en) * 2013-07-29 2016-05-12 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
WO2015104666A2 (en) * 2014-01-09 2015-07-16 Torrent Pharmaceuticals Limited Pharmaceutical composition of fingolimod

Also Published As

Publication number Publication date
AU2016331648A1 (en) 2018-05-17
CA3000186A1 (en) 2017-04-06
EP3355863A4 (en) 2019-06-19
IL258420A (en) 2018-05-31
BR112018006648A2 (pt) 2018-10-23
WO2017058364A1 (en) 2017-04-06
EP3355863A1 (en) 2018-08-08
US20180280322A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
CL2019003264A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
MX2016010213A (es) Formulaciones farmaceuticas novedosas.
WO2015160842A8 (en) Methods and formulations of capsaicinoids and capsinoids
WO2015160843A8 (en) Ion channel activators and methods of use
MX2013001677A (es) Formulaciones estables de linaclotida.
MX2011007817A (es) Formulacion farmaceutica o alimenticia de liberacion controlada y proceso para su preparacion.
PH12015501913A1 (en) Substituted imidazopyridazines
WO2015171460A3 (en) Formulations of cyclophosphamide liquid concentrate
PE20150199A1 (es) Composiciones farmaceuticas y tratamiento de mastitis
MX364800B (es) Tilmicosina de accion prolongada mejorada y el uso de la misma en el tratamiento del complejo respiratorio bovino (crb) y en el periodo de la vaca seca.
MX2016001422A (es) Composicion farmaceutica de fingolimod.
PH12016502544B1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
PH12019501424A1 (en) Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor
PH12016500414B1 (en) Solid preparation containing choline alfoscerate and method for preparing same
MX2018004021A (es) Formulaciones estables de fingolimod.
WO2014166836A8 (en) Growth hormone compound formulation
MX365972B (es) Composiciones para el cuidado bucal.
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
MX2015016679A (es) Formulaciones de agomelatina que comprenden agomelatina en forma de cocristales.
MX2015009077A (es) Composicion estable que contiene fingolimod.
AU2017260019A1 (en) Valerian composition and related methods
IN2014MU00284A (es)
WO2015165571A3 (en) Solid oral formulations comprising solid melt dispersions of organic acids in xylitol
PH12019501049A1 (en) Pharmaceutical composition containing palonosetron as active ingredient